CanBas Co., Ltd.
Tokyo Stock Exchange 4575.T
CanBas Co., Ltd. Gross Profit for the year ending June 30, 2024: USD -6.13 M
CanBas Co., Ltd. Gross Profit is USD -6.13 M for the year ending June 30, 2024, a -31.79% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
-
CanBas Co., Ltd. Gross Profit for the year ending June 30, 2023 was USD -4.65 M, a -3.83% change year over year.
-
CanBas Co., Ltd. Gross Profit for the year ending June 30, 2022 was USD -4.48 M, a -54.95% change year over year.
-
CanBas Co., Ltd. Gross Profit for the year ending June 30, 2021 was USD -2.89 M, a 6.02% change year over year.
-
CanBas Co., Ltd. Gross Profit for the year ending June 30, 2020 was USD -3.07 M.
Key data
| Date | Gross Profit | Operating Income | EBIT | EBITDA |
|---|
Market news
Loading...
Tokyo Stock Exchange: 4575.T
| CEO | Mr. Takumi Kawabe M.D., Ph.D. |
| IPO Date | Sept. 17, 2009 |
| Location | Japan |
| Headquarters | 2-2-1, Otemachi |
| Employees | 11 |
| Sector | Health Care |
| Industries | |
Description
CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email